Lab 21 Acquires Independent Clinical Laboratory Diagnostics Company

(Suffolk, UK), an independent clinical laboratory company providing diagnostic testing services for the UK National Health Service (NHS; UK) and private healthcare providers in the United Kingdom and parts of Europe. The financial terms of the transaction were not disclosed.

A global provider of diagnostic products and services, Lab21 supports drug discovery, healthcare, and environmental monitoring. Its customers include healthcare providers, pharmaceutic and biotechnology companies, in addition to organizations that need to monitor their impact on the environment. The company has a growing test portfolio providing companion diagnostics and high technology assays for the growing integration of personalized medicine into healthcare. These services and products are currently in infectious diseases, oncology, and pharmacogenetics areas with emerging interests in cardiovascular and metabolic disease.

The acquisition of NPTech significantly broadens Lab21's range of diagnostic tests. NPTech brings food intolerance testing; chemical and mold sensitivity testing; blood tests for a range of conditions; basic clinical chemistry; and salivary hormone testing. NPTech has multiple other diagnostic tests for a variety of clinical disorders including salivary tests for adrenal hormones, sex hormones, and sleep disturbance together with a range of clinical biochemistry blood testing, particularly in the area of thyroid disease diagnosis and management.

NPTech has a diverse range of international customers. Not only does the acquisition extend Lab21 interests into the allergy market, it also significantly develops its underlying clinical chemistry capability to support its cutting-edge products.

Graham Mullis, CEO of Lab21, said: "This is an excellent acquisition for Lab21. NPTech's range of services complement those already offered by Lab21, and will significantly enhance the range of tests we can offer. I am also delighted that NPTech is the first of what will be a number of acquisitions during 2008.”


Related Links:
Lab21
NPTech
National Health Service